Literature DB >> 6310035

The effect of cycloheximide on the accumulation and stability of functional alpha-mRNA in cells infected with herpes simplex virus.

M L Fenwick, J Clark.   

Abstract

Cells were infected with herpes simplex virus type 2, HSV-2(G), and incubated in the presence of cycloheximide (CX). When CX was removed and actinomycin D (Act D) added, alpha-polypeptides ICP 0 and ICP 4 were synthesized at low rates. If CX was removed without adding Act D, the rate of production of ICP 4 increased while that of ICP 0 remained constant. In cells treated with azetidine to enhance the production of ICP 4 and 0, accumulation of functional mRNA for ICP 4 (determined indirectly by translation in vivo) was reduced by concentrations of CX between 0.5 and 5.0 micrograms/ml, whereas mRNA for ICP 0 was unaffected by 50 micrograms/ml CX. CX apparently either inhibits the synthesis of ICP 4 mRNA or enhances its inactivation without affecting the production or degradation of ICP 0 mRNA. The accumulation of ICP 4 or ICP 0 mRNA of HSV-1(F) was unaffected by CX. The low levels of ICP 4 and ICP 0 mRNAs of HSV-2(G) that accumulated in the presence of CX disappeared rapidly after adding Act D, in contrast to those of HSV-1(F) which were stable. The ICP 4 mRNA of HSV-2(G) was stable, however, if made without CX or if in mixed infection with HSV-1(F) in the presence of CX. It is suggested that rapid inactivation may account for the low level of accumulation of functional ICP 4 and ICP 0 mRNAs of HSV-2(G) in the presence of CX, and that ICP 4 mRNA is protected by a protein made soon after normal infection. Such a protein may be carried in the virion of HSV-1(F).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310035     DOI: 10.1099/0022-1317-64-9-1955

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Differential regulation of endogenous and transduced beta-globin genes during infection of erythroid cells with a herpes simplex virus type 1 recombinant.

Authors:  C A Smibert; J R Smiley
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  In vitro mRNA degradation system to study the virion host shutoff function of herpes simplex virus.

Authors:  C R Krikorian; G S Read
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  The virion host shutoff protein of herpes simplex virus type 1: messenger ribonucleolytic activity in vitro.

Authors:  B D Zelus; R S Stewart; J Ross
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

4.  A single regulatory region modulates both cis activation and trans activation of the herpes simplex virus VP5 promoter in transient-expression assays in vivo.

Authors:  E D Blair; E K Wagner
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  Expression and function of the equine herpesvirus 1 virion-associated host shutoff homolog.

Authors:  X Feng; Y G Thompson; J B Lewis; G B Caughman
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Replication origins and a sequence involved in coordinate induction of the immediate-early gene family are conserved in an intergenic region of herpes simplex virus.

Authors:  J L Whitton; J B Clements
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

7.  Analysis of the HSV-2 early AG-4 antigen.

Authors:  L A Evans; M Sheppard; J T May
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

8.  Degradation of cellular mRNAs induced by a virion-associated factor during herpes simplex virus infection of Vero cells.

Authors:  N Schek; S L Bachenheimer
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Human cytomegalovirus major immediate early transcripts arise predominantly from the canonical major immediate early promoter in reactivating progenitor-derived dendritic cells.

Authors:  Rebecca Mason; Ian J Groves; Mark R Wills; John H Sinclair; Matthew B Reeves
Journal:  J Gen Virol       Date:  2020-06       Impact factor: 3.891

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.